EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial
Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101ESO-101, EsoCap’s lead product candidate, consists of a…